SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: 52-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL WITH SUBCUTANEOUS DOSING

被引：0

作者：

Hall, Stephen ^{[1
]}

Kavanaugh, Arthur ^{[2
]}

McInnes, Iain ^{[3
]}

Mease, Philip ^{[4
]}

Chinoy, Hector ^{[5
]}

Kivitz, Alan ^{[6
]}

Patekar, Manmath ^{[7
]}

Wang, Z. ^{[8
]}

Mpofu, Shephard ^{[9
]}

机构：

[1] Monash Univ, Melbourne, Vic 3004, Australia

[2] Univ Calif San Diego, Sch Med, San Diego, CA USA

[3] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland

[4] Univ Washington, Swedish Med Ctr, Seattle, WA 98195 USA

[5] Univ Manchester, Manchester M13 9PL, Lancs, England

[6] Altoona Ctr Clin Res, Duncansville, PA USA

[7] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India

[8] Novartis Pharmaceut, E Hanover, NJ USA

[9] Novartis Pharma AG, Basel, Switzerland

来源：

INTERNAL MEDICINE JOURNAL | 2016年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ARA-P88

引用

页码：38 / 39

页数：2

共 50 条

[1] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing
Kavanaugh, Arthur
McInnes, Iain B.
Mease, Philip J.
Hall, Stephan
Chinoy, Hector
Kivitz, Alan J.
Patekar, Manmath
Wang, Zailong
Mpofu, Shephard
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[2] Secukinumab provides sustained improvements in the signs and symptoms of Active Psoriatic Arthritis in Anti. TNF-Naive patients and those previously exposed to Anti-TNF Therapy: 52-week results from a randomized, double-blind, placebo-controlled phase 3 trial with subcutaneous dosing
Hall, S.
Kavanaugh, A.
McInnes, I.
Mease, P.
Chinoy, H.
Kivitz, A.
Patekar, M.
Wang, Z.
Mpofu, S.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 53 - 53
[3] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: 52-WEEK RESULTS FROM AN INTERNATIONAL PHASE 3 TRIAL
Kavanaugh, Arthur
Kivitz, Alan
McInnes, Iain B.
Mease, Philip
Mpofu, Shephard
Wang, Zailong
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 141 - 142
[4] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials
Baeten, Dominique
Blanco, Ricardo
Geusens, Piet
Sieper, Joachim
Tseng Jui-Cheng
Martin, Ruvie
Porter, Brian
Richards, Hanno
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[5] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TOANTI-TNF THERAPY: 52-WEEK RESULTS FROM TWO INTERNATIONAL PHASE 3 TRIALS
Deodhar, Atul
Baeten, Dominique
Blanco, Ricardo
Sieper, Joachim
Martin, Ruvie
Porter, Brian
Richards, Hanno
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 137 - 138
[6] SECUKINUMAB EFFICACY IN ANTI-TNF-NAIVE PATIENTS AND PATIENTS PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY (MEASURE 2) IN ACTIVE ANKYLOSING SPONDYLITIS
Sieper, J.
Braun, J.
Baraliakos, X.
Baeten, D. L.
Dougados, M.
Emery, P.
Deodhar, A.
Porter, B.
Andersson, M.
Richards, H.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 272 - 272
[7] Secukinumab Efficacy in Anti-TNF-Naive Patients and Patients Previously Exposed to Anti-TNF Therapy: Results of A Randomized, Double-Blind, Placebo- Controlled Phase 3 Study (MEASURE 2) in Active Ankylosing Spondylitis
Jean, Dudler
Braun, J.
Baraliakos, X.
Baeten, D.
Dougados, M.
Emery, P.
Deodhar, A.
Porter, B.
Andersson, M.
Richards, H.
SWISS MEDICAL WEEKLY, 2016, 146 : 7S - 7S
[8] SECUKINUMAB EFFICACY IN ANTI-TNF-NAIVE AND ANTI-TNF-IR PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF A PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 2)
Kavanaugh, A.
McInnes, I. B.
Hall, S.
Chinoy, H.
Kivitz, A.
Kandala, S.
Patekar, M.
Mpofu, S.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 345 - 346
[9] Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
Hasan Tahir
Atul Deodhar
Mark Genovese
Tsutomu Takeuchi
Jacob Aelion
Filip Van den Bosch
Sibylle Haemmerle
Hanno B. Richards
Rheumatology and Therapy, 2017, 4 : 475 - 488
[10] Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
Tahir, Hasan
Deodhar, Atul
Genovese, Mark
Takeuchi, Tsutomu
Aelion, Jacob
Van den Bosch, Filip
Haemmerle, Sibylle
Richards, Hanno B.
RHEUMATOLOGY AND THERAPY, 2017, 4 (02) : 475 - 488

← 1 2 3 4 5 →